Lemtrada (alemtuzumab) / Sanofi 
Welcome,         Profile    Billing    Logout  
 8 Diseases   17 Trials   17 Trials   2602 News 


«12345678910111213...2425»
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    Disseminated Histoplasmosis after Alemtuzumab () -  Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_1088;    
    Conclusion To our knowledge, this is the fourth report of histoplasmosis after alemtuzumab, and the first in a patient who received it for T-PLL (Figure 3). Disseminated histoplasmosis can be a potential infectious complication of the profound immunosuppression resulting from alemtuzumab and the underlying diseases it is used to treat, and should be considered in patients with unexplained cytopenias or other systemic symptoms, particularly in endemic areas.
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty, Lemtrada (alemtuzumab) / Sanofi
    Alemtuzumab following natalizumab in pediatric- and adult-onset multiple sclerosis () -  Nov 20, 2022 - Abstract #AECF2022AECF_7;    
    ALZ seems more effective in AOMS than in POMS following NTZ. Additional studies are needed to clarify whether ALZ (or more broadly, induction therapies) might be an effective therapeutic approach for POMS, especially when shifting from NTZ, and if an addition ALZ course should be always considered in younger patients, especially in POMS.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Review, Journal:  High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis. (Pubmed Central) -  Nov 10, 2022   
    In this review, we provide an overview of the DMT options and MS treatment strategies, and discuss the clinical benefits of HETs (including ofatumumab, ocrelizumab, natalizumab, alemtuzumab, and cladribine) in the early stages of MS, along with safety concerns associated with these DMTs. By minimizing the accumulation of neurological damage early in the disease course, early treatment with HETs may enhance long-term clinical outcomes over the lifetime of the patient.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    ALEMTUZUMAB‐INDUCED AUTOIMMUNE THYROID DISEASE‐ CLINICAL AND BIOCHEMICAL COURSE () -  Oct 26, 2022 - Abstract #ATA2022ATA_460;    
    Thirty‐nine (39%) developed autoimmune thyroid disease, of whom 35 patients (30%) had GD. Median time from first dose of alemtuzumab to diagnosis of thyroid disease was 25 (range 12‐64) months.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    COVID-19 immunity in Multiple Sclerosis: Living with MS on DMTs a year after COVID-19 vaccination (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_2057;    
    Aims and Objectives: To evaluate if people with MS on and off disease modification treatments) (DMT) develop and maintain adequate adaptive immune response after the completed course of Covid-19 vaccination compared to healthy controls (HC) We recruited people with MS on and off DMT (n=210; Ocrelizumab, Alemtuzumab, Natalizumab, Fingolimod, Tecfidera, Interferon, no-DMT n=30 each) and HC (n=30) a year since 1st covid-19 vaccine. This study presents novel data informing care of People with MS and vaccination policies.
  • ||||||||||  Socioeconomic Influence on DMT Prescribing Strategies (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_2000;    
    This difference was seen early in the study with all levels of socioeconomic status trending toward similar rates of high efficacy prescribing by the end. The cause for this lower rate of high-efficacy prescribing will require further evaluation; one theory is that patient assistance programs may distort the economics of DMT affordability for this quartile of patients.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Horizontal versus vertical switch of treatment in patients with relapsing-remitting multiple sclerosis in Austria (ePoster Theatre 4) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1847;    
    A horizontal switch after a platform therapy revealed a higher relapse probability and a trend towards less EDDS improvements comparing to a vertical switch in Austrian RRMS patients. Therefore, switching to a higher efficacy treatment should be preferred in the case of treatment failure.
  • ||||||||||  DMT Persistence: we've started, when will we stop? (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1766;    
    This multi-centre study has revealed highly variable persistence between DMTs over time, which may impact real-world effectiveness. These results may inform DMT clinical decision-making and improve outcomes for pwMS.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    COVID-19 Severity and Vaccination Effect in Persons with MS Treated with Alemtuzumab (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1594;    
    There is no evidence of any increased risk for severe COVID-19 in pwMS treated with alemtuzumab. In these patients, humoral response to anti-SARS-CoV-2 vaccine was high and comparable to those treated with other DMTs or untreated.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Clinical characteristics and disability progression in late-onset MS (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1404;    
    Around half of the treated LOMS (54.5%) had been exposed to high efficacy therapies (fingolimod, natalizumab, rituximab, ocrelizumab, alemtuzumab, daclizumab and HSCT) compared to almost two thirds of AOMS (66.1 %). Significant differences in clinical characteristics, treatment approaches and risk for disability progression distinguish LOMS from AOMS.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Transcriptome alterations in peripheral blood B cells of patients with multiple sclerosis under immune reconstitution therapy (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1314;    
    We show that B cells circulating in the blood of patients with MS under IRT present a distinct gene expression signature, and we delineated the associated biological processes and gene interactions. Moreover, we identified candidate genes whose expression may be an indicator of relapse risk, but further studies are needed to substantiate their potential predictive value.
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty, Lemtrada (alemtuzumab) / Sanofi
    Shifting from Natalizumab to Alemtuzumab in Pediatric-Onset Multiple Sclerosis (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1116;    
    In POMS shifting from natalizumab, alemtuzumab is an effective option. The moderate NEDA condition needs to be further evaluated compared with pediatric cohorts not treated with alemtuzumab and with alemtuzumab-treated adult-onset MS.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Effective humoral and cellular immunity in mRNA-COVID-19 multiple sclerosis vaccinees treated with alemtuzumab (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1062;    
    P=N/A
    We prospectively measured (1) SARS-COV-2 IgG response using a quantitative anti-spike protein-based immunoassay (Euroimmun, Lubeck, Germany, cut-off IgG level >35.2 BAU/ml), (2) memory B-cells specific for SARS-CoV-2 RBD, and (3) memory T-cells secreting IFN-g and/or IL-2, in response to SARS-CoV-2 peptides by ELISpot/Fluorospot assays, in MS patients vaccinated with BNT162b2-COVID-19 vaccine before, one and three months after the second vaccine dose. Alemtuzumab treatment enabled effective humoral and cellular immune responses at 1 month and 3 months following COVID-19 vaccination.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Horizontal versus vertical switch of treatment in patients with relapsing-remitting multiple sclerosis in Austria (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_825;    
    A horizontal switch after a platform therapy revealed a higher relapse probability and a trend towards less EDDS improvements comparing to a vertical switch in Austrian RRMS patients. Therefore, switching to a higher efficacy treatment should be preferred in the case of treatment failure.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    The brain-age paradigm and clinical outcomes in multiple sclerosis (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_682;    
    Results indicate that MS patients exhibit accelerated brain aging; greater brain-PAD was observed among those diagnosed atyounger age and with higher EDSS. More severe longitudinal changes in brain-PAD are observed in the early stage of the disease, among patients with a shorter disease duration, and could be used as biomarker to monitor treatment response.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    Journal:  Consensus statement on the use of alemtuzumab in daily clinical practice in Spain. (Pubmed Central) -  Oct 11, 2022   
    Further data are needed to better understand potential paradigm shifts in DMT use in women of childbearing age. The present document is intended to be used as a tool for optimising the management of alemtuzumab in routine clinical practice.